127 related articles for article (PubMed ID: 4038406)
1. Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
Flameng W; Van de Werf F; Vanhaecke J; Verstraete M; Collen D
J Clin Invest; 1985 Jan; 75(1):84-90. PubMed ID: 4038406
[TBL] [Abstract][Full Text] [Related]
2. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
[TBL] [Abstract][Full Text] [Related]
3. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
[TBL] [Abstract][Full Text] [Related]
4. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
5. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
[TBL] [Abstract][Full Text] [Related]
7. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
Groves R; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
[TBL] [Abstract][Full Text] [Related]
8. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Chen L; Nichols WW; Mattsson C; Teger-Nilsson AC; Saldeen TG; Mehta JL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1276-83. PubMed ID: 8667188
[TBL] [Abstract][Full Text] [Related]
9. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
10. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
11. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Gold HK; Fallon JT; Yasuda T; Leinbach RC; Khaw BA; Newell JB; Guerrero JL; Vislosky FM; Hoyng CF; Grossbard E
Circulation; 1984 Oct; 70(4):700-7. PubMed ID: 6541103
[TBL] [Abstract][Full Text] [Related]
12. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
13. [Intracoronary thrombolytic treatment with urokinase in myocardial infarct: clinical angiographic findings and effects on left ventricular function].
Ibba GV; Terrosu P; Franceschino V; Contini G; Frau G
G Ital Cardiol; 1983 Aug; 13(8):75-84. PubMed ID: 6653959
[TBL] [Abstract][Full Text] [Related]
14. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
[TBL] [Abstract][Full Text] [Related]
15. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
[TBL] [Abstract][Full Text] [Related]
16. [Optimal reperfusion therapy in acute myocardial infarction: time to reperfusion and recanalization rate].
Mochida Y; Kimura K; Kosuge M; Yoshida K; Iwasawa Y; Hongo Y; Sugiyama M; Ishikawa T; Kuji N; Tochikubo O; Ishii M
J Cardiol; 1998 May; 31(5):255-62. PubMed ID: 9617655
[TBL] [Abstract][Full Text] [Related]
17. Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study.
Kopia GA; Kopaciewicz LJ; Ruffolo RR
J Pharmacol Exp Ther; 1988 Mar; 244(3):956-62. PubMed ID: 3252043
[TBL] [Abstract][Full Text] [Related]
18. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Lu HR; Gold HK; Wu Z; Yasuda T; Pauwels P; Rapold HJ; Napier M; Bunting S; Collen D
Thromb Haemost; 1992 Jun; 67(6):686-91. PubMed ID: 1509410
[TBL] [Abstract][Full Text] [Related]
19. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
Van de Werf F; Bergmann SR; Fox KA; de Geest H; Hoyng CF; Sobel BE; Collen D
Circulation; 1984 Mar; 69(3):605-10. PubMed ID: 6362907
[TBL] [Abstract][Full Text] [Related]
20. Endocardial and epicardial infarct size after preconditioning by a partial coronary artery occlusion without intervening reperfusion. Importance of the degree and duration of flow reduction.
Koning MM; Gho BC; van Klaarwater E; Duncker DJ; Verdouw PD
Cardiovasc Res; 1995 Dec; 30(6):1017-27. PubMed ID: 8746219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
